Orthocell Limited

OCC

AU000000OCC6

Advanced Medical Equipment & Technology

Delayed Australian S.E. Other stock markets 08:15:48 10/02/2026 am IST			5-day change	1st Jan Change
0.9900 ^AUD	+5.88%		+3.66%	-8.76%

02/02	Orthocell Eyes Fiscal 2027 Entry Into UK, European Union Markets	MT
19/01	Orthocell posts quarterly revenue of A$3.2 million	RE

Orthocell finalises strategic investment in Marine Biomedica

Published on 01/16/2026 at 06:54 am IST

Reuters

Latest news about Orthocell Limited

02/02	Orthocell Eyes Fiscal 2027 Entry Into UK, European Union Markets	MT
19/01	Orthocell posts quarterly revenue of A$3.2 million	RE
16/01	Orthocell Finalizes Agreement With Biotechnology Company	MT
16/01	Orthocell finalises strategic investment in Marine Biomedica	RE
06/01	Orthocell posts A$3.2 million in revenue for quarter ended 31 December	RE
06/01	Orthocell Posts 45% Revenue Growth for December 2025 Quarter	MT
18/12	Orthocell Sells 100 Units of Nerve Repair Product in US	MT
17/12	Canaccord Genuity Starts Orthocell at Speculative Buy with AU$1.33 Price Target	MT
15/12	Orthocell Submits Application to the British Standards Institution for Approval for Commercial Distribution of Nerve Repair Product, Shares Up 3%	MT
15/12	Orthocell submits regulatory application for commercial distribution of Remplir	RE
10/12	Orthocell Sells Nerve Repair Product in Hong Kong	MT
20/11	Orthocell Limited Announces Adoption of Remplir by Australian Urologists	CI
20/11	Orthocell To Set Up Commercialization Advisory Board for Nerve Repair Product, Shares Up 7%	MT
06/11	Orthocell Reports Sixth Consecutive Quarter of Record Revenue in September Quarter	MT
05/11	Orthocell Appoints Second Distributor in Canada for Nerve Repair Product	MT
03/11	Orthocell Says First Nerve Repair Product Surgical Case in Hong Kong Completed, Shares Up 4%	MT
29/25/29	ASX Midday Sector Update: Materials Stocks Up, Healthcare Continues to Struggle	MT
29/25/29	Orthocell Appoints MontsMed as Exclusive Distributor for Remplir in Hong Kong	MT
29/25/29	Orthocell Appoints MontsMed as Its Exclusive In-Country Distributor for Hong Kong	CI
20/25/20	Orthocell secures rights to high-value bone regeneration tech	RE
20/25/20	Orthocell Signs MoU with Biotechnology Company; Shares Up 3%	MT
19/25/19	Marine Biomedical announced that it expects to receive AUD 1.05 million in funding from Orthocell Limited	CI
17/25/17	Orthocell says a$30m placement sees co positioned for rapid growth	RE
17/25/17	Orthocell to Raise AU$30 Million via Placement	MT
15/25/15	Orthocell requests trading halt for proposed capital raising	RE

Orthocell Limited is an Australia-based regenerative medicine company. The Company is focused on regenerating mobility for patients by developing products for the repair of a variety of bone and soft tissue injuries. Its portfolio of products includes Striate+, Remplir, and OrthoACI. Striate+ is a sterile, resorbable collagen membrane used for guided bone and tissue regeneration in dental applications. Remplir is a collagen scaffold used in peripheral nerve repair. OrthoACI or autologous chondrocyte implantation is used for the treatment of articular cartilage defects in the knee and ankle. OrthoACI uses the patientâ€™s own healthy cartilage cells called chondrocytes to assist the regeneration of damaged cartilage. The Company is engaged in the development of its tendon cell therapy in the United States. Its autologous tendon therapy is an advanced injectable cellular therapy for the treatment of chronic tendon injuries.

Employees

Sector

Advanced Medical Equipment & Technology

Calendar

03/03 - Q2 2026 Earnings Release (Projected)

More about the company